A
Andrew C. von Eschenbach
Researcher at University of Texas MD Anderson Cancer Center
Publications - 118
Citations - 11419
Andrew C. von Eschenbach is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Prostate cancer & Prostate. The author has an hindex of 52, co-authored 117 publications receiving 11243 citations. Previous affiliations of Andrew C. von Eschenbach include University of Texas at Austin & Texas Medical Center.
Papers
More filters
Journal ArticleDOI
Prostate cancer radiation dose response: results of the m. d. anderson phase iii randomized trial
Alan Pollack,Gunar K. Zagars,George Starkschall,John A. Antolak,J. Jack Lee,Eugene Huang,Andrew C. von Eschenbach,Deborah A. Kuban,Isaac I. Rosen +8 more
TL;DR: An increase of 8 Gy resulted in a highly significant improvement in FFF for patients at intermediate-to-high risk, although the rectal reactions were also increased.
Journal ArticleDOI
Identification of p53 gene mutations in bladder cancers and urine samples
David Sidransky,Andrew C. von Eschenbach,Yvonne C. Tsai,Peter A. Jones,Ian C. Summerhayes,Fray F. Marshall,Meera Paul,Pearl A Green,Stanley R. Hamilton,Philip Frost,Bert Vogelstein +10 more
TL;DR: The p53 mutations are the first genetic alterations demonstrated to occur in a high proportion of primary invasive bladder cancers, and Detection of such mutations ex vivo has clinical implications for monitoring individuals whose tumor cells are shed extracorporeally.
Journal ArticleDOI
American Cancer Society Guidelines for the Early Detection of Cancer: Update of Early Detection Guidelines for Prostate, Colorectal, and Endometrial Cancers: ALSO: Update 2001—Testing for Early Lung Cancer Detection
Robert A. Smith,Andrew C. von Eschenbach,Richard C. Wender,Bernard Levin,Tim Byers,David A. Rothenberger,Durado Brooks,William T. Creasman,Carmel J. Cohen,Carolyn D. Runowicz,Debbie Saslow,Vilma Cokkinides,Harmon J. Eyre +12 more
TL;DR: The authors review the “cancer‐related check‐up,” clinical encounters that provide case‐finding and health counseling opportunities, and the ACS is issuing an updated narrative related to testing for early lung cancer detection for clinicians and individuals at high risk of lung cancer in light of emerging data on new imaging technologies.
Journal Article
Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
George N. Thalmann,Ploutarchos E. Anezinis,Shi Ming Chang,Haiyen E. Zhau,E. Edmund Kim,Vicki L. Hopwood,Sen Pathak,Andrew C. von Eschenbach,Leland W.K. Chung +8 more
TL;DR: It is demonstrated that one of the LNCaP sublines derived from C4-2 tumors that metastasized to the lymph node and bone acquired metastatic potential.
Journal ArticleDOI
Preliminary Results of a Randomized Radiotherapy Dose-Escalation Study Comparing 70 Gy With 78 Gy for Prostate Cancer
Alan Pollack,Gunar K. Zagars,L.G. Smith,J. Jack Lee,Andrew C. von Eschenbach,John A. Antolak,George Starkschall,Isaac I. Rosen +7 more
TL;DR: A modest dose increase of 8 Gy using conformal radiotherapy resulted in a substantial improvement in prostate cancer FFF rates for patients with a pretreatment PSA of more than 10 ng/mL, document that local persistence of prostate cancer in intermediate- to high-risk patients is a major problem when doses of 70 Gy or less are used.